[UPDATE: Sparta told Medtech Insight that it expects to submit its preclinical data to the FDA by the fall and start its first clinical trial of the Ormi hydrogel by the end of the year. Patients interested in being considered for the trial should talk to their surgeon about the trial's inclusion criteria: Kellgren Lawrence classification of 0 to 3, medial or lateral condyle lesions with ICRS classification III or IV, and total treatable area of 2-10cm2.To contact the company, use the contact form on the website,spartabiomedical.com.]
Sparta Biomedical is confident its Ormi hydrogel knee implant will eventually enable patients to quickly return to normal activities that would be too
